Targeted therapy Leveraging ADCC to enhance anti-HER2 therapy

被引：5
|
作者：
Killock, David
机构：
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 04期
关键词：
D O I：
10.1038/nrclinonc.2017.19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：200 / 200
页数：1
相关论文
共 50 条
  • [41] Anti-HER2 immunoliposomes for targeted drug delivery
    Park, JW
    Kirpotin, D
    Hong, K
    Colbern, G
    Shalaby, R
    Shao, Y
    Meyer, O
    Nielsen, U
    Marks, J
    Benz, CC
    Papahadjopoulos, D
    MEDICINAL CHEMISTRY RESEARCH, 1998, 8 (7-8) : 383 - 391
  • [42] Molecular basis and possibilities for modulation of resistance to anti-HER2 therapy
    Harbeck, N.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (12) : 1226 - 1226
  • [43] Anti-HER2 vaccines: new prospects for breast cancer therapy
    Ladjemi, Maha Zohra
    Jacot, William
    Chardes, Thierry
    Pelegrin, Andre
    Navarro-Teulon, Isabelle
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (09) : 1295 - 1312
  • [44] Prediction of response to anti-HER2 therapy using multigene assay
    Atallah, N.
    Makhlouf, S.
    Li, X.
    Zhangy, Y.
    Mongan, N.
    Rakha, E.
    BREAST, 2025, 80
  • [45] When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab
    Zimmer, Alexandra S.
    Denduluri, Neelima
    CURRENT ONCOLOGY REPORTS, 2019, 21 (12)
  • [46] Neratinib and the Role of Anti-HER2 Therapy in Salivary Duct Carcinoma
    Napolitano, Martina
    Trudu, Lucia
    Martinelli, Enrica
    Santini, Chiara
    Dominici, Massimo
    Bertolini, Federica
    CANCER REPORTS, 2025, 8 (01)
  • [47] When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab
    Alexandra S. Zimmer
    Neelima Denduluri
    Current Oncology Reports, 2019, 21
  • [48] Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy
    Chen, Huaiwen
    Gao, Jie
    Lu, Ying
    Kou, Geng
    Zhang, He
    Fan, Li
    Sun, Zhiguo
    Guo, Yajun
    Zhong, Yanqiang
    JOURNAL OF CONTROLLED RELEASE, 2008, 128 (03) : 209 - 216
  • [49] Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
    Chen, Zifan
    Chen, Yang
    Sun, Yu
    Tang, Lei
    Zhang, Li
    Hu, Yajie
    He, Meng
    Li, Zhiwei
    Cheng, Siyuan
    Yuan, Jiajia
    Wang, Zhenghang
    Wang, Yakun
    Zhao, Jie
    Gong, Jifang
    Zhao, Liying
    Cao, Baoshan
    Li, Guoxin
    Zhang, Xiaotian
    Dong, Bin
    Shen, Lin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [50] Specific anti-HER2 host immunity conferred by HER2-targeted antibody drug conjugate therapy and checkpoint blockade.
    Qin, You
    Dobson, Hannah E.
    Comer, Frank I.
    Chang, Alfred E.
    Wicha, Max S.
    Li, Qiao
    CANCER RESEARCH, 2021, 81 (13)
12345